

## Special Issue

# CRISPR-Mediated Cancer Modeling

### Message from the Guest Editor

CRISPR technology has revolutionized many areas of research, including cancer research. The possibility to easily generate loss of function studies by the application of CRISPR has opened new possibilities of research. In addition, gain of function studies can be conducted by homologues repaired after CRISPR breaks. This has allowed research to model common loss or gain of function mutations that occur in cancer. CRISPR technology is now used for genome-wide screening by the application of large libraries as well as temporal gene activation or inhibition. Furthermore, as these technologies are both applied in vitro and in vivo, this has opened new research avenues regarding the complexity of cancer biology. This Special Issue will focus on cancer research where CRISPR technology has been applied, with the aim to publish articles where the authors' application of technology has provided new insight into cancer biology.

---

### Guest Editor

Dr. Martin Kristian Thomsen  
Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark

---

### Deadline for manuscript submissions

closed (31 May 2022)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/81093](https://mdpi.com/si/81093)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)